Cardiotoxicity Manifestations in Metastatic Breast Cancer Patients Treated With Trastuzumab as First Line

Data from a retrospective analysis of patients with metastatic breast cancer who received first-line trastuzumab—presented during the 2020 ASCO Virtual Scientific Program—suggest that every-3-month echocardiogram may not be the optimal cadence for LVEF monitoring in this patient population and that less frequent monitoring may be sufficient.

2020 ASCO Virtual Scientific Program